Venture Visionary Partners LLC Has $11.61 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Venture Visionary Partners LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 81.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,026 shares of the company's stock after selling 309,361 shares during the period. Venture Visionary Partners LLC's holdings in Johnson & Johnson were worth $11,613,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Highline Wealth Partners LLC grew its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. von Borstel & Associates Inc. bought a new position in Johnson & Johnson during the first quarter worth $49,000. Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the first quarter worth $52,000. Finally, Capital A Wealth Management LLC bought a new position in Johnson & Johnson during the fourth quarter worth $50,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock traded up $0.7890 during midday trading on Wednesday, reaching $178.5890. 9,028,878 shares of the company's stock traded hands, compared to its average volume of 8,462,277. The company has a 50-day simple moving average of $162.59 and a two-hundred day simple moving average of $158.87. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $180.61. The company has a market cap of $430.10 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 2.26 and a beta of 0.41. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the firm posted $2.82 EPS. The business's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Finally, Royal Bank Of Canada upped their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.